163 related articles for article (PubMed ID: 24752990)
21. MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1.
Azijli K; Yuvaraj S; van Roosmalen I; Flach K; Giovannetti E; Peters GJ; de Jong S; Kruyt FA
Apoptosis; 2013 Jul; 18(7):851-60. PubMed ID: 23456625
[TBL] [Abstract][Full Text] [Related]
22. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.
Sordella R; Bell DW; Haber DA; Settleman J
Science; 2004 Aug; 305(5687):1163-7. PubMed ID: 15284455
[TBL] [Abstract][Full Text] [Related]
23. TBK1-targeted suppression of TRIF-dependent signaling pathway of toll-like receptor 3 by auranofin.
Park SJ; Lee AN; Youn HS
Arch Pharm Res; 2010 Jun; 33(6):939-45. PubMed ID: 20607500
[TBL] [Abstract][Full Text] [Related]
24. Suppression of the TRIF-dependent signaling pathway of Toll-like receptors by luteolin.
Lee JK; Kim SY; Kim YS; Lee WH; Hwang DH; Lee JY
Biochem Pharmacol; 2009 Apr; 77(8):1391-400. PubMed ID: 19426678
[TBL] [Abstract][Full Text] [Related]
25. Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms.
Sutterlüty H; Mayer CE; Setinek U; Attems J; Ovtcharov S; Mikula M; Mikulits W; Micksche M; Berger W
Mol Cancer Res; 2007 May; 5(5):509-20. PubMed ID: 17510316
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of RalA signaling pathway in treatment of non-small cell lung cancer.
Male H; Patel V; Jacob MA; Borrego-Diaz E; Wang K; Young DA; Wise AL; Huang C; Van Veldhuizen P; O'Brien-Ladner A; Williamson SK; Taylor SA; Tawfik O; Esfandyari T; Farassati F
Lung Cancer; 2012 Aug; 77(2):252-9. PubMed ID: 22498113
[TBL] [Abstract][Full Text] [Related]
27. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
[TBL] [Abstract][Full Text] [Related]
28. shRNA kinome screen identifies TBK1 as a therapeutic target for HER2+ breast cancer.
Deng T; Liu JC; Chung PE; Uehling D; Aman A; Joseph B; Ketela T; Jiang Z; Schachter NF; Rottapel R; Egan SE; Al-Awar R; Moffat J; Zacksenhaus E
Cancer Res; 2014 Apr; 74(7):2119-30. PubMed ID: 24487029
[TBL] [Abstract][Full Text] [Related]
29. The role of TBK1 in cancer pathogenesis and anticancer immunity.
Runde AP; Mack R; S J PB; Zhang J
J Exp Clin Cancer Res; 2022 Apr; 41(1):135. PubMed ID: 35395857
[TBL] [Abstract][Full Text] [Related]
30. Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer.
Kitajima S; Ivanova E; Guo S; Yoshida R; Campisi M; Sundararaman SK; Tange S; Mitsuishi Y; Thai TC; Masuda S; Piel BP; Sholl LM; Kirschmeier PT; Paweletz CP; Watanabe H; Yajima M; Barbie DA
Cancer Discov; 2019 Jan; 9(1):34-45. PubMed ID: 30297358
[No Abstract] [Full Text] [Related]
31. Identification of proangiogenic genes and pathways by high-throughput functional genomics: TBK1 and the IRF3 pathway.
Korherr C; Gille H; Schäfer R; Koenig-Hoffmann K; Dixelius J; Egland KA; Pastan I; Brinkmann U
Proc Natl Acad Sci U S A; 2006 Mar; 103(11):4240-5. PubMed ID: 16537515
[TBL] [Abstract][Full Text] [Related]
32. A review on the role of TANK-binding kinase 1 signaling in cancer.
Alam M; Hasan GM; Hassan MI
Int J Biol Macromol; 2021 Jul; 183():2364-2375. PubMed ID: 34111484
[TBL] [Abstract][Full Text] [Related]
33. Vitamin D Alleviates Rotavirus Infection through a Microrna-155-5p Mediated Regulation of the TBK1/IRF3 Signaling Pathway In Vivo and In Vitro.
Zhao Y; Ran Z; Jiang Q; Hu N; Yu B; Zhu L; Shen L; Zhang S; Chen L; Chen H; Jiang J; Chen D
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31330869
[TBL] [Abstract][Full Text] [Related]
34. STK33 kinase activity is nonessential in KRAS-dependent cancer cells.
Babij C; Zhang Y; Kurzeja RJ; Munzli A; Shehabeldin A; Fernando M; Quon K; Kassner PD; Ruefli-Brasse AA; Watson VJ; Fajardo F; Jackson A; Zondlo J; Sun Y; Ellison AR; Plewa CA; San MT; Robinson J; McCarter J; Schwandner R; Judd T; Carnahan J; Dussault I
Cancer Res; 2011 Sep; 71(17):5818-26. PubMed ID: 21742770
[TBL] [Abstract][Full Text] [Related]
35. The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy.
Liu S; Marneth AE; Alexe G; Walker SR; Gandler HI; Ye DQ; Labella K; Mathur R; Toniolo PA; Tillgren M; Gokhale PC; Barbie D; Mullally A; Stegmaier K; Frank DA
Blood Adv; 2018 Dec; 2(23):3428-3442. PubMed ID: 30504235
[TBL] [Abstract][Full Text] [Related]
36. Tyrosine phosphorylation of IRF3 by BLK facilitates its sufficient activation and innate antiviral response.
Li WW; Fan XX; Zhu ZX; Cao XJ; Zhu ZY; Pei DS; Wang YZ; Zhang JY; Wang YY; Zheng HX
PLoS Pathog; 2023 Oct; 19(10):e1011742. PubMed ID: 37871014
[TBL] [Abstract][Full Text] [Related]
37. Selective TBK1/IKKi dual inhibitors with anticancer potency.
Li J; Huang J; Jeong JH; Park SJ; Wei R; Peng J; Luo Z; Chen YT; Feng Y; Luo JL
Int J Cancer; 2014 Apr; 134(8):1972-80. PubMed ID: 24150799
[TBL] [Abstract][Full Text] [Related]
38. ALS-associated missense and nonsense TBK1 mutations can both cause loss of kinase function.
de Majo M; Topp SD; Smith BN; Nishimura AL; Chen HJ; Gkazi AS; Miller J; Wong CH; Vance C; Baas F; Ten Asbroek ALMA; Kenna KP; Ticozzi N; Redondo AG; Esteban-Pérez J; Tiloca C; Verde F; Duga S; Morrison KE; Shaw PJ; Kirby J; Turner MR; Talbot K; Hardiman O; Glass JD; de Belleroche J; Gellera C; Ratti A; Al-Chalabi A; Brown RH; Silani V; Landers JE; Shaw CE
Neurobiol Aging; 2018 Nov; 71():266.e1-266.e10. PubMed ID: 30033073
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit.
Zhu Z; Aref AR; Cohoon TJ; Barbie TU; Imamura Y; Yang S; Moody SE; Shen RR; Schinzel AC; Thai TC; Reibel JB; Tamayo P; Godfrey JT; Qian ZR; Page AN; Maciag K; Chan EM; Silkworth W; Labowsky MT; Rozhansky L; Mesirov JP; Gillanders WE; Ogino S; Hacohen N; Gaudet S; Eck MJ; Engelman JA; Corcoran RB; Wong KK; Hahn WC; Barbie DA
Cancer Discov; 2014 Apr; 4(4):452-65. PubMed ID: 24444711
[TBL] [Abstract][Full Text] [Related]
40. Kinome-wide siRNA screen identifies a DCLK2-TBK1 oncogenic signaling axis in clear cell renal cell carcinoma.
Hu L; Zhang Y; Guo L; Zhong H; Xie L; Zhou J; Liao C; Yao H; Fang J; Liu H; Zhang C; Zhang H; Zhu X; Luo M; von Kriegsheim A; Li B; Luo W; Zhang X; Chen X; Mendell JT; Xu L; Kapur P; Baldwin AS; Brugarolas J; Zhang Q
Mol Cell; 2024 Feb; 84(4):776-790.e5. PubMed ID: 38211588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
